Clinical Infectious Diseases · 2021 · 15 citations · 10 references
T-p Vancomycin TreatmentMedical MicrobiologyTapered-pulsed Fidaxomicin RegimenHealth SciencesAntimicrobial StewardshipAntibioticsAntimicrobial SusceptibilityAntibiotic AdjuvantFidaxomicin RegimenAntimicrobial ChemotherapyMicrobiologyInfection ControlMedicineClinical MicrobiologyAntimicrobial ResistanceT-p Fidaxomicin ShowsDrug Resistance
We treated 46 patients with multiple recurrent Clostridioides difficile infections (mrCDI) using a tapered-pulsed (T-P) fidaxomicin regimen, the majority of whom failed prior T-P vancomycin treatment. Sustained clinical response rates at 30 and 90 days were 74% (34/46) and 61% (28/46). T-P fidaxomicin shows promise for management of mrCDI.
10
Fidaxomicin versus Vancomycin for <i>Clostridium difficile</i> Infection
Thomas Louie, Mark A. Miller, Kathleen M. Mullane et al. · New England Journal of Medicine · 2011 · 1.6K citations · Full text
Oliver A. Cornely, Derrick W. Crook, Roberto Esposito et al. · The Lancet Infectious Diseases · 2012 · 739 citations
Fidaxomicin Versus Vancomycin, Antimicrobial Susceptibility, Health Sciences +8
Thomas Louie, Kristine Cannon, Brendan Byrne et al. · Clinical Infectious Diseases · 2012 · 299 citations · Full text
Dysbiosis, Pathology, Cdi Symptoms +18
Benoît Guéry, Francesco Menichetti, Veli-Jukka Anttila et al. · The Lancet Infectious Diseases · 2017 · 208 citations · Full text
Benjamin D Sirbu, Melinda M. Soriano, Carl Manzo et al. · Clinical Infectious Diseases · 2017 · 61 citations · Full text
Vancomycin Taper, Antimicrobial Susceptibility, Health Sciences +12